suptavumab

This page shows the latest suptavumab news and features for those working in and with pharma, biotech and healthcare.

US, EU regulators back rapid reviews of AZ’s RSV med

Another rival, Regeneron’s antibody suptavumab (REGN2222), was dropped from development in 2017 after a late-stage trial failure.

AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi

The prospects for both of AZ’s drugs for RSV prevention took an upturn last year, when a potential rival – Regeneron’s suptavumab – was dropped from development after missing its targets
AZ says target of $45bn sales by 2023 still achievable

Q3 revenues topped analyst expectations
Regeneron and Bayer drop AMD combination

This is the second pipeline disappointment for Regeneron in recent months after it abandoned respiratory syncytial virus (RSV) candidate suptavumab, which failed to hit the mark in a phase III trial
Regeneron drops RSV drug

Suptavumab failed to prevent the infections in re-term infants. Regeneron has said it will end the development of its late-stage candidate for the prevention of respiratory syncytial virus (RSV) ... infection. The trial enrolled 1, 149 infants who were